Angion Biomedica Corp (ANGN): Price and Financial Metrics

Angion Biomedica Corp (ANGN): $10.00

0.20 (+2.04%)

POWR Rating

Component Grades








Add ANGN to Watchlist
Sign Up

Industry: Biotech




#70 of 437

in industry

ANGN Price/Volume Stats

Current price $10.00 52-week high $10.60
Prev. close $0.98 52-week low $0.46
Day low $8.90 Volume 22,480
Day high $10.60 Avg. volume 86,718
50-day MA $0.71 Dividend yield N/A
200-day MA $0.82 Market Cap 301.14M

ANGN Stock Price Chart Interactive Chart >

Angion Biomedica Corp (ANGN) Company Bio

Angion Biomedica Corp. operates as a late-stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica serves customers in the State of New York.

ANGN Latest News Stream

Event/Time News Detail
Loading, please wait...

ANGN Latest Social Stream

Loading social stream, please wait...

View Full ANGN Social Stream

Latest ANGN News From Around the Web

Below are the latest news stories about ANGION BIOMEDICA CORP that investors may wish to consider to help them evaluate ANGN as an investment opportunity.

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | April 27, 2023

Angion (ANGN) Down on Merger Agreement With Private Biotech

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Yahoo | January 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today!

William White on InvestorPlace | January 17, 2023

Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLO

Yahoo | January 17, 2023

Bullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)

Multiple insiders secured a larger position in Angion Biomedica Corp. ( NASDAQ:ANGN ) shares over the last 12 months...

Yahoo | December 27, 2022

Read More 'ANGN' Stories Here

ANGN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 51.52%
3-year -94.23%
5-year N/A
2023 0.00%
2022 -72.01%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!